💥 Gate Square Event: #PostToWinCC 💥
Post original content on Gate Square related to Canton Network (CC) or its ongoing campaigns for a chance to share 3,334 CC rewards!
📅 Event Period:
Nov 10, 2025, 10:00 – Nov 17, 2025, 16:00 (UTC)
📌 Related Campaigns:
Launchpool: https://www.gate.com/announcements/article/48098
CandyDrop: https://www.gate.com/announcements/article/48092
Earn: https://www.gate.com/announcements/article/48119
📌 How to Participate:
1️⃣ Post original content about Canton (CC) or its campaigns on Gate Square.
2️⃣ Content must be at least 80 words.
3️⃣ Add the hashtag #PostTo
The showdown of "weight loss miracle drugs": Lilly's Zepbound beats Novo Nordisk's Wegovy
On December 4th, Jinshi Data reported that Eli Lilly and Company stated that, in the first comparative trial of two blockbuster weight-loss drugs, the performance of the company’s weight-loss drug Zepbound outperformed Wegovy (Victoza) from Novo Nordisk. In a study sponsored by Eli Lilly, subjects taking Zepbound lost an average of 20% of their weight - about 50 pounds - over 72 weeks, while those taking Wegovy lost 14%. This result confirmed previous trials of these two drugs, which showed that Zepbound had a stronger effect. The side effects of the two drugs are mainly related to the gastrointestinal tract and are similar. Lilly stated that the complete study results will be published in a peer-reviewed journal and will be presented at medical conferences next year. In Copenhagen, Novo Nordisk’s stock price fell by 1.8%, and it has pumped about 11% this year. Lilly’s (LLY.N) stock price pumped 2% before the opening of the US stock market.